The role of targeting mammalian target of rapamycin in lung cancer.
The expression of mammalian target of rapamycin (mTOR) might be upregulated by various mechanisms in lung cancer pathogenesis, and its activity might be modulated by pathways related to tobacco-mediated carcinogenesis. Furthermore, preclinical data suggest an antitumor effect in lung cancer from a class of agents that antagonize the mTOR pathway. Consistent with this, initial clinical trials of mTOR inhibitors suggest some activity in the setting of both non-small-cell lung carcinoma and small-cell lung carcinoma. Herein, we explore the relationship of mTOR to lung carcinogenesis and further describe clinical trials of mTOR inhibitors alone and in combination with chemotherapeutic and targeted agents.
Pal
Sumanta Kumar
SK
Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Figlin
Robert A
RA
Reckamp
Karen L
KL
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000378:metabolism; D018288:Carcinoma, Small Cell / Q000188:drug therapy / Q000378:metabolism; D002986:Clinical Trials as Topic; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011494:Protein Kinases / Q000378:metabolism*; D058570:TOR Serine-Threonine Kinases
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases